by To Siu Hang. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (leaves 84-92). / Abstract also in Chinese. / Declaration --- p.i / Abstract --- p.ii / Acknowledgement --- p.vi / Abbreviations --- p.vii / List of Figures --- p.viii / List of Tables --- p.xii / Content --- p.xiv / Chapter 1. --- INTRODUCTION --- p.1 / Chapter 1.1. --- Osteosarcoma --- p.1 / Chapter 1.1.1. --- Incidence / Chapter 1.1.2. --- Age and Sex Distribution / Chapter 1.1.3. --- Clinical Features / Chapter 1.1.4. --- Treatment / Chapter 1.2. --- Adriamycin --- p.9 / Chapter 1.2.1. --- Drug Action / Chapter 1.2.2. --- Pharmacology / Chapter 1.3. --- Multidrug Resistance --- p.11 / Chapter 1.4. --- P-glycoprotein --- p.13 / Chapter 1.4.1. --- Nature / Chapter 1.4.2. --- Tissue Distribution / Chapter 1.4.3. --- Relation with MDR / Chapter 1.5 --- Multidrug Resistance Protein --- p.16 / Chapter 1.6. --- Reactive Oxygen Species --- p.17 / Chapter 1.6.1. --- Problems Arising from ROS / Chapter 1.6.2. --- Oxidative Stress and Diseases / Chapter 1.6.3. --- Defense System / Chapter 1.6.4. --- Antioxidative Enzymes / Chapter 1.6.5. --- Relation with MDR / Chapter 1.7. --- Topoisomerase II --- p.22 / Chapter 1.8. --- Methods to Detect MDR --- p.24 / Chapter 1.8.1. --- P-glycoprotein Immunohistochemistry / Chapter 1.8.2. --- Adriamycin Binding Assay / Chapter 1.9. --- Aims of Study --- p.25 / Chapter 2. --- MATERIALS AND METHODS --- p.27 / Chapter 2.1. --- Clinical Study --- p.27 / Chapter 2.1.1. --- Patients Recruitment / Chapter 2.1.2. --- Adriamycin Binding Assay / Chapter 2.1.3. --- P-glycoprotein Immunohistochemistry / Chapter 2.1.3.1. --- Sample and Control Preparation / Chapter 2.1.3.2. --- Immunohistochemical Procedure / Chapter 2.1.4. --- Tumour Necrosis Assessment / Chapter 2.2. --- Effect of Adriamycin on Osteosarcoma Cells --- p.32 / Chapter 2.2.1. --- Establishment of Adriamycin Adapted Osteosarcoma Cells / Chapter 2.2.1.1. --- Maintenance and Subculture of SaOS-2 Cell Line / Chapter 2.2.1.2. --- Storage of Cell Line / Chapter 2.2.1.3. --- Adriamycin Treatment / Chapter 2.2.2. --- KB-V1 Cell Culture / Chapter 2.2.3. --- Adriamycin Binding Assay / Chapter 2.2.4. --- P-glycoprotein Immunohistochemistry / Chapter 2.2.4.1. --- Sample and Control Preparation / Chapter 2.2.4.2. --- Immunohistochemical Procedures / Chapter 2.2.5. --- Thymidine Incorporation Assay / Chapter 2.2.5.1. --- Assay Procedures / Chapter 2.2.6. --- Catalase Assay / Chapter 2.2.6.1. --- Assay Procedures / Chapter 2.2.6.2. --- Unit Calculation / Chapter 2.2.7. --- Glutathione Peroxidase Assay / Chapter 2.2.7.1. --- Assay Procedures / Chapter 2.2.7.2. --- Unit Calculation / Chapter 2.2.8. --- Protein Determination / Chapter 2.3. --- Statistical Analysis --- p.45 / Chapter 3. --- RESULTS --- p.46 / Chapter 3.1. --- Clinical Study --- p.46 / Chapter 3.1.1. --- Patients Recruitment / Chapter 3.1.2. --- Correlation of Adriamycin Sensitivity to Tumour Necrosis / Chapter 3.1.3. --- Correlation of P-glycoprotein Expression to Tumour Necrosis / Chapter 3.1.4. --- Correlation of P-glycoprotein Expression to Adriamycin Sensitivity / Chapter 3.2. --- Effect of Adriamycin on Osteosarcoma Cells --- p.63 / Chapter 3.2.1. --- Adriamycin Sensitivity and P-glycoprotein Expression / Chapter 3.2.2. --- Thymidine Incorporation Rate / Chapter 3.2.3. --- Intracellular Concentration of Catalase / Chapter 3.2.4. --- Intracellular Concentration of Glutathione Peroxidase / Chapter 4. --- DISCUSSIONS --- p.71 / Chapter 4.1. --- Clinical Study --- p.71 / Chapter 4.1.1. --- Patients Recruitment / Chapter 4.1.2. --- Correlation between Adriamycin Sensitivity and Tumour Necrosis / Chapter 4.1.3. --- Correlation between P-glycoprotein Expression and Tumour Necrosis / Chapter 4.1.3.1. --- P-glycoprotein Is Induced During Chemotherapy / Chapter 4.1.3.2. --- P-glycoprotein Cannot Serve As a Prognostic Factor / Chapter 4.1.4. --- Correlation Between Adriamycin Sensitivity and P-glycoprotein Expression / Chapter 4.2. --- Effect of Adriamycin on Osteosarcoma Cells --- p.76 / Chapter 4.2.1. --- Adriamycin Sensitivity and P-glycoprotein Expression / Chapter 4.2.2. --- Proliferation Rate / Chapter 4.2.3. --- Antioxidative Enzymes Activities / Chapter 5. --- CONCLUSION --- p.82 / Chapter 6. --- FURTHER STUDY --- p.83 / Chapter 7. --- BIBLIOGRAPHY --- p.84 / Chapter 8. --- APPENDIX - SOLUTIONS PREPARATION --- p.93

Drug development is a long and expensive process. Potential drug candidates can fail clinical trials due to numerous issues, including metabolic stability and efficacy issues, wasting years of research effort and resource. This thesis detailed the development of in silico methods to predict the metabolic stability of structures and their bioavailability. Coralie Atom-based Statistical SOM Identifier (CASSI) is a site of metabolism (SOM) predictor which provides a SOM prediction based on statistical information gathered about previously seen atoms present in similar environments. CASSI is a real-time SOM predictor accessible via graphical user interface (GUI), allowing users to view the prediction results and likelihood of each atom to undergo different types of metabolic transformation. Fast Metabolizer (FAME)1 is a ligand-based SOM predictor developed around the same time by Kirchmair et al. In the course of the evaluation of CASSI and FAME performance, the two concepts were combined to produce FamePrint. FamePrint is a tool developed within the Coralie Cheminformatics Platform developed by Lhasa Limited. which can carry out SOM predictions, as well as bioisosteric replacement identification. Same as CASSI, this is available via the Coralie application GUI. The bioavailability issues caused by the metabolic enzyme, cytochrome P450 3A4, and transporter protein P-gylcoprotein are also investigated in this work, along with the potential synergistic relationship between the two systems. In silico classifiers to distinguish substrates against non-substrates of the two systems are produced and it was envisaged that these classifiers can be integrated into FamePrint as an additional layer of information available to the user when deciding on bioisosteric replacements to use when optimising a compound.

La glycoprotéine VI (GP VI) des plaquettes sanguines humaines est le récepteur principal du collagène, composé le plus thrombogénique d'une paroi vasculaire lésée. Ainsi, GPVI est souvent considérée comme une cible de premier plan pour développer des tests diagnostiques ou des stratégies thérapeutiques innovantes, efficaces et sûres afin d'améliorer encore la prise en charge des accidents ischémiques. Les anticorps monoclonaux et leurs fragments actifs produits par ingénierie moléculaire constituent aujourd'hui une nouvelle classe de biomolécules en plein essor avec des propriétés bien adaptées à des applications thérapeutiques et diagnostiques. Notre groupe a produit plusieurs anticorps monoclonaux anti-GPVI par immunisation génique de souris. Ces anticorps ont une affinité élevé pour leur cible. Ils de distinguent les uns des autres par leur spécificité épitopique ainsi que par les effets engendrés par leur liaison à GPVI. Parmi ces anticorps, l'un présente un fort potentiel diagnostique parce qu'il reconnait les formes mono- et dimériques de GPVI, mais sa liaison aux plaquettes peut induire une activation ou la perte de GPVI. Un autre anticorps présente un fort potentiel thérapeutique parce que ses fragments actifs monovalents obtenus par papaïnolyse neutralisent l'interaction entre les plaquettes et le collagène, sans activer les plaquette. Cependant, l'origine xénogénique de cet anticorps est responsable d'une forte immunogénicité qui en interdit des applications en médecine humaine. Dans cette étude, nous avons conçus un fragments variable d'anticorps simple chaine (scFv) utile pour quantifier l'expression de la GPVI à la surface des plaquettes sanguines. Ce scFv a été reformaté de façon à lui insérer un motif de reconnaissance de la Protéine L (PpL) qui facilite sa détection et sa purification sans avoir recours à un peptide "drapeau". Nous avons également humanisé et créé plusieurs fragments d'anticorps recombinants monovalents inhibiteurs de l'interaction GPVI / collagène. Ces fragments d'anticorps présentent un potentiel thérapeutique élevé. / Human platelets glycoprotein VI (GPVI) is evidenced to be a platelet receptor of major importance in the occurrence of arterial thrombosis. Thus, it can be considered to be of great interest in diagnosis and therapeutic of atheriosclerotic diseases. Antibodies are powerful molecules which can be used in both diagnostic as well as for therapeutic purposes due to their unique characteristics. Monoclonal and recombinant antibodies have antigen restricted specificity, high affinity and can be used in various assays. Moreover, the good knowledge of their structure and molecular engineering facilities now allows the antibody modulation according to desired properties.Our group has already produced several monoclonal antibodies to human GPVI by gene gun immunization against the immunoadhesin hGPVI-Fc, which differ in fine epitopespecificity, affinity and other functional properties (Lecut et al. 2003). One, 3J24, with diagnostic potential while the other, 9O12, has a therapeutic potential because it blocks the binding of GPVI to collagen. Its Fab fragment has been extensively characterized in vitro,ex vivo and in vivo for its antithrombotic properties.Here, we designed and reshaped a single-chain antibody fragment (scFv) based on 3J24variable domains for the quantification of GPVI with diagnostic potential. We were also involved in the design, production and functional evaluation of humanized anti-GPVI recombinant antibody fragments (scFvs and Fabs) with therapeutic properties.

La surexpression de protéines d’efflux, et tout particulièrement la P-glycoprotéine, est impliquée dans la multidrug résistance. Dans cette thèse, nous démontrons que le vandetanib, inhibiteur de tyrosine kinase, est à la fois substrat et inhibiteur de la P-glycoprotéine et qu’il est capable de réverser in vitro la résistance à la doxorubicine liée à la surexpression de la P-glycoprotéine.Nous nous sommes également intéressés à l’étude du passage transplacentaire du vandetanib et nous montrons que ce médicament traverse la barrière placentaire. / Overexpression of ABC transporters, especially P-glycoprotein, is involved in multidrug resistance. In this study, we demonstrate that vandetanib, a tyrosine kinase inhibitor, is both substrate and inhibitor of P-glycoprotein and is able to reverse in vitro resistance to doxorubicin, linked to overexpression of P-glycoprotein.We also studied the placental transfer of vandetanib and we show that this drug crosses the placenta.

A resistência natural do gambá Didelphis marsupialis ao veneno de serpentes se deve a fatores antibiotrópicos presentes em seu soro, do qual DM43 é um dos responsáveis pela inibição da atividade hemorrágica. Com o objetivo de entender melhor o mecanismo de ação desta proteína contra a metaloprotease contida no veneno pretendeu-se, neste trabalho, otimizar as condições de cristalização de DM43, na tentativa de determinar sua estrutura por difração de raios-X. Ensaios de cristalização revelaram que o sulfato de amônio é o precipitante mais eficiente na produção de cristais de DM43. A visualização e indexação dos padrões de difração destes cristais permitiram apenas a determinação dos parâmetros de sua cela unitária, devido a baixa qualidade dos mesmos. Deste modo, os seguintes parâmetros de cela unitária foram encontrados: a = b = 117.34 (0.03) Å, c = 193.39 (0.02)Å, ?=?=90° e ? = 120°, correspondentes ao sistema cristalino trigonal ou hexagonal. A recente determinação da sequência de aminoácidos de DM43, possibilitou modelar sua estrutura tridimensional por homologia utilizando o método de satisfação das restrições espaciais. Os três domínios tipo imunoglobulina de DM43 foram modelados em duas partes a partir da estrutura de referência KIR2DL1(1nkr) homóloga a dois domínios C-terminais de DM43, com apenas 27.72% de identidade. O domínio N-terminal denominado D0, foi modelado separadamente contra o domínio C-terminal de KIR2DL1 com um grau de identidade igual a 28.89%. A partir do programa GRASP e PATCHES, foram detectadas as prováveis regiões de ligação entre as duas partes da molécula e uma possível região responsável pela dimerização no domínio D2 de DM43. Interessantemente, resíduos polares em KIR2DLs que foram substituídos por hidrofóbicos em DM43, concentrando-se em uma face do domínio D2 ausente de sítios de glicosilação, o que coincide com as observações de dimerização do receptor do hormônio de crescimento. Um motivo estrutural característico de receptores hematopoiéticos identificados como WSXWS box, foi encontrado em todos os domínios de DM43, especialmente no domínio D2. Supõe-se que a sua existência esteja relacionada com a orientação relativa dos domínios por manter o primeiro triptofano do motivo posicionado exatamente na interface entre os domínios. Surge ainda uma fita extra (F´), no domínio D2, não pertencente ao enovelamento imunoglobulina devido a presença da Pro273, muito bem conservada, a três resíduos do motivo WSXWS. Esta fita parece desempenhar um papel importante na orientação do motivo pois além de formar ligações de hidrogênio com a fita G do domínio anterior, posiciona corretamente o primeiro triptofano do motivo na interface. Somando-se a isto, a presença de resíduos hidrofóbicos na interface dos domínios D1 e D2pode estar contribuindo para a orientação angular relativa menor que 90° entre os dois domínios. Uma interpretação análoga a de hormônios de crescimento sugere que, os loops entre as fitas AB, CC´ e EF do domínio 1, BC e FG do domínio 2 e o linker entre estes dois domínios, estejam envolvidos na interação da metaloprotease com DM43. / The natural resistance of the opossum, Didelphis marsupialis, towards snake venom is due to antibothropic factors present in the blood serum, of which DM43 is one. It is responsible for the inhibition of the hemorrhagic activity of the venom. With a view to better understanding the mechanism of action of this protein against venom metalloproteases, one of the aims of the present work was to optimize the crystallization conditions of DM43 in order to determine its three-dimensional structure by X-ray diffraction. Crystallization trials revealed that ammonium sulphate was the best precipitant. Visualization and indexing of the diffraction patterns from such crystals only allowed for the determination of the unit cell parameters due to their inherently low quality. The values obtained were a = b = 117.34 (0.03) \'ANGSTRON\', c = 193.39 (0.02) Å, ?=?= 90° e ? = 120°, corresponding to the trigonal or hexagonal crystal systems. The recent determination of the amino acid sequence of DM43 permitted the homology modelling of its three-dimensional structure by satisfaction of spatial restraints. The three immunoglobulin-like domains of DM43 were modelled in two separate parts from the reference structure KIR2DL1 (1nkr), homologous to the two C-terminal domains of DM43, with which its shares 27.72% sequence identity. The N-terminal domain, denominated D0, was separately modelled based on the C-terminal domain of KIR2DL1, with which it shares 28.89% identity. The programs PATCHES and GRASP were used to detect the probable interface region between the two separate parts of the molecule as well as a region probably responsible for dimerisation. Polar residues in KIR2DL1 which had been substituted by hydrophobic residues in DM43 are observed concentrated on one face of the molecule devoid of glycosilation sites (D2) coinciding with the dimerisation interface observed in the growth hormone receptor. A structural motif characteristic of the haematopoetic receptor family, identified as the WSXWS box, was observed to some extent in all three domains of DM43 and most evident in domain D2. It is speculated that the existence of this motif is related to the relative orientation of the domains, by maintaining the first tryptophan of the motif positioned at the domain interface. An additional ?-strand (F) in D2, which is not characteristic of the immunoglobulin fold, is observed due to the presence of the conserved Pro273, three-residues prior to the WSXWS box. This strand appears to play an important role in correctly positioning the motif as it forms hydrogen bonds with strand G of the previous domain thus orientating the first tryptophan of the motif at the interface. The presence of hydrophobic residues at the interdomain interface, may also contribute to stabilizing the acute angular relationship between D1 and D2. An analogous interpretation to that given for the growth hormone receptor, suggests that the loops between ?-strands AB, CC\' and EF of domain D1 and between strands BC and FG do domain D2 plus the linker region, are involved in the binding of metalloproteinase by DM43.

In healthy airways, mucus forms part of the innate immune response protecting the respiratory epithelium from damage by pathogens and environmental debris (Rose and Voynow, 2006). Conversely, in many respiratory diseases, mucus becomes part of the airway disease pathology. Mucus hypersecretion along with reduced clearance can cause blockage of the small airways, impairing gas exchange, promoting inflammation and becoming a culture medium for bacterial colonisation (Thornton et al., 2008). Recurrent airway obstruction (RAO) is a common yet poorly understood equine chronic respiratory disease where such altered mucus properties and clearance have been identified as major factors in the disease pathology (Davis and Rush, 2002; Gerber et al., 2000; Kaup et al., 1990; Robinson, 2001). The gel-forming mucins are largely responsible for the transport properties of mucus. The major equine airway gel-forming mucin in health is Muc5b and to a lesser extent Muc5ac; produced in specialised respiratory epithelial goblet cells and sub-mucosal glands (Rousseau et al., 2011b). Changes in mucin relative and net amounts and their macromolecular properties and interactions have been attributed to the altered physical properties of airway mucus in airways disease (Groneberg et al., 2002a; Jefcoat et al., 2001; Kirkham et al., 2002; Robinson et al., 2003; Sheehan et al., 1995).The project investigates the biochemical properties of mucins present in mucus from healthy horses and horses with RAO. This project identifies the anatomical presence of mucin-producing goblet cells and glands in fixed tissues from the respiratory tracts of healthy horses and subsequently examines mucin-production sites in respiratory tracts from horses with RAO. Finally the project investigates a methodology for the study of mucin production in airway cells harvested from live horses suffering from RAO.Our investigations confirmed that horses with RAO have more endotracheal mucus than healthy controls, and that Muc5b is the predominant mucin with Muc5ac also present in RAO horse mucus, both during symptomatic disease and when horses are asymptomatic. Mucins are produced in epithelial goblet cells and sub-mucosal glands dispersed throughout the length and circumference of the equine trachea and bronchi. Goblet cell hyperplasia occurs in symptomatic exposed RAO horse airways, although goblet cells are smaller than in asymptomatic RAO horse airways. Exposure to a dusty stable environment is associated with more goblet cells per length of bronchial compared to tracheal epithelium in all horses. RAO horses have larger sub-mucosal glands containing more mucin than control horses. Primary epithelial cell cultures grown at an air liquid interface are an alternative approach to study equine airway mucus, although the use of this culture system is in its early stages. We have developed novel ways to harvest equine airway epithelial cells (tracheal brushing) and shown it is possible to freeze cells collected via tracheal epithelial brushing in 20 % FBS and then culture to ALI at a later date.

Este estudo teve como objetivo avaliar as alterações do complexo de glicoproteínas associadas à distrofina que conferem estabilidade estrutural aos cardiomiócitos na isquemia miocárdica induzida pelo isoproterenol. Materiais e Métodos: Ratos Wistar machos foram divididos em dois grupos: grupo controle (SAL), injeção subcutânea de salina, e grupo isoproterenol (ISO), injeção subcutânea de isoproterenol (85mg/kg) diluído em água destilada, em dois dias consecutivos separados por intervalo de 24hs. Os ratos foram mortos 24 horas após a segunda injeção de salina ou isoproterenol. Os corações foram rapidamente excisados, lavados em salina gelada, pesados e colocados em formol PBS por 24hs a 4ºC e incluídos em parafina ou Historesina. Para análise morfométrica, os corações foram cortados transversalmente na porção medioventricular, equidistante entre o ápice e a base, e incluídos em parafina. Áreas dos ventrículos direito e esquerdo, espessura de parede livre dos ventrículos e septo interventricular foram medidas. Os corações cortados frontalmente nas metades anterior e posterior e incluídos em Historesina foram utilizados para avaliação das áreas de miocitólise. Porções hemiventriculares foram congeladas para as reações de imunofluorescência com os seguintes marcadores: distrofina, ?-1 integrina, ?-actina sarcomérica, ?-sarcoglicana, ?-distroglicana, merosina laminina, albumina, CD68, CD45, CD4 e eNOS. A apoptose foi avaliada através do método de TUNEL. A função cardíaca, as dimensões das cavidades ventriculares e a mobilidade de parede foram analisadas através da ecocardiografia. A análise estatística foi realizada através do teste t de Student, com nível de significância de 5%. Resultados e Conclusão: Houve diferença significativa no peso do coração, na taxa de crescimento corporal, na área do ventrículo esquerdo e na espessura de parede do ventrículo direito entre os grupos. Não houve diferença estatística significativa na espessura da parede do ventrículo esquerdo e septo, mas observou-se tendência à diminuição. As áreas de miocitólise representaram 26,89%, 36,12%, 28,15% no ventrículo direito, septo e ventrículo esquerdo, respectivamente. A imunofluorescência mostrou que a distrofina foi a estrutura mais sensível ao dano provocado pelo isoproterenol, seguida pela perda completa da actina. A redução na expressão de ?-sarcoglicana, ?-distroglicana, ?-1 integrina e laminina, foram considerados como epifenômenos. A expressão de eNOS estava praticamente ausente nas áreas de miocitólise. A expressão aumentada de eNOS nos pequenos vasos ao redor das áreas de miocitólise sugere uma resposta compensatória à isquemia provocada pelo isoproterenol na tentativa de melhora do fluxo sangüíneo para as áreas de lesão. Foi observada alteração na permeabilidade sarcolemal nos cardiomiócitos dos animais tratados com isoproterenol com acúmulo de albumina no espaço intracelular. Observou-se que os cardiomiócitos e os macrófagos estavam constante e claramente marcados para apoptose nas áreas de miocitólise. Na ecocardiografia, os diâmetros sistólico e diastólico do ventrículo esquerdo foram significativemente maiores no grupo ISO em comparação com os controles. A fração de ejeção não foi diferente entre os grupos. O escore de mobilidade de parede mostrou hipocinesia ou acinesia nos segmentos apicais nos corações do grupo ISO. Essas mudanças, relacionadas à isquemia, podem explicar as graves alterações na integridade estrutural do sarcolema dos cardiomiócitos e a lesão induzida pelo isoproterenol. Mecanismos compensatórios no curto período de nosso experimento poderiam manter a função cardíaca normal apesar das graves alterações morfológicas encontradas. / This study tested the hypothesis that the dystrophin-glycoprotein complex that confers structural stability in cardiomyocytes was affected in the isoproterenol-induced myocardial ischemia. Materials and Methods: Male Wistar rats were divided in control group (SAL), injected subcutaneously with physiological saline, and isoproterenol-treated group (ISO), injected with isoproterenol (85mg/Kg) diluted in distilled water, in two consecutive days, separated by a 24-hour interval. These rats were killed 24 hours after the second injection of isoproterenol or physiological saline. The hearts were rapidly removed, rinsed in ice-cold 0.9% saline solution, weighed, and fixed as a whole in phosphate-buffered for 24 hours at 4oC. For morphometric analysis, the hearts cut into two fragments by a midventricular coronal section and embedded in paraffin. The absolute thicknesses of the septum and left and right ventricular walls and the areas of each ventricular chamber were measured. The hearts for Historesin embedding were frontally cut into anterior and posterior halves for analysis of myocytolytic areas. Hearts frontally cut were frozen for immunofluorescence study using primary antibodies against dystrophin, ?-1 integrin, ?- sarcomeric actin, ?-sarcoglycan, ?-dystroglycan, merosin laminin, albumin, CD68, CD45, CD4 e eNOS. The occurrence of apoptotic cells was evaluated by TUNEL method. The cardiac function, LV dimensions and wall motion segmented score were analyzed by echocardiography. For analysis of differences between the two groups the Student\'s t-test was performed and the level of significance of 5% was chosen to denote difference between means. Results and Conclusion: There was significant difference in the heart weight, in the heart ratio, in the LV area and right ventricular (RV) thicknesses between the two groups. No statistical difference was observed in the thicknesses of the free wall of the LV and septum, although tended to be lower in isoproterenol-treated myocardium. The percentage of myocytolysis in the LV, septum, and RV with myocytolysis in isoproterenol treated rats was: 26.89%, 36.12%, 28.15%, respectively. Immunofluorescence demonstrated that loss of dystrophin was the primary event in the myocytolytic process. Decreased expression of ?-dystroglycan, ?-sarcoglycan, ?-1 integrin and laminin occurred, appearing as epiphenomena. The eNOS expression was almost completely absent in the myocytolytic foci. eNOS expression was enhanced in blood vessels of cardiomyocytes through the entire myocardium of rats given isoproterenol. This is likely a compensatory response to the ischemic insult elicited by isoproterenol administration. In the myocytolytic foci a positive reaction for apoptosis was constantly and clearly noted in cardiomyocytes and macrophages. The echocardiography showed that diastolic and systolic LV dimensions in ISO-group were significantly higher in comparison with control group. The ejection fraction was not different between groups. The wall motion segmented score showed hypokinesis or akinesis in the apical segments in the hearts of ISO-group as compared with controls. These changes, related to ischemic injury, can explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol. Compensatory mechanisms in the short time of our experiment could maintain the normal cardiac function in spite of severe myocardial morphological changes.

Human respiratory syncytial virus (HRSV) is a negative sense, single strand RNA virus that causes respiratory tract infection with common cold-like symptoms, which can be severe in children, immunocompromised, and the elderly. Even with 60 years of research, the need for vaccine and effective treatment has not been met. In this work, recombinant viruses have been generated which will be valuable in gaining a better understanding of HRSV subtypes, glycoprotein evolution, and the polymerase localization, which would contribute to HRSV vaccine and therapeutics development. The differences in the fitness of A and B antigenic subtypes of HRSV and how it affects the regional circulation pattern is not well understood. To study and compare the two subtypes, it is important to use clinically relevant recombinant viruses and to use animal models that best represent human infection. Using a wild-type virus strain (A11 and B05) from each HRSV subtype, a wild-type like recombinant (r) virus, rHRSVA11, and recombinant viruses expressing fluorescent proteins, rHRSVA11EGFP(5) and rHRSVB05dTom(5), were generated. Characterization of rB05 viruses demonstrated that the differences in the fluorescent protein expressed did not affect virus growth kinetics. To prepare for an experiment in cotton rats, recombinant HRSVs generated were used to infect cotton rat lung cells in vitro. With confirmation of infection of cotton rat lung cells by rHRSV, cotton rat co-infection experiment was planned for the recombinant A11 and B05 viruses and a microneutralization assay was developed for post-infection processing of the in vivo samples. The BA genotype of HRSV B subtype is a strain of HRSV B subtype containing a 60 nucleotide duplication in the glycoprotein (G) gene. HRSV BA genotype was first isolated in 1998 and has quickly become the predominant genotype circulating globally. Although a role of immune evasion by the strains of BA genotype has been suggested to explain this phenomenon, few studies have supported this hypothesis. To compare the HRSV B subtype virus with and without the duplication, rB05 virus lacking the duplication, rHRSVB05EGFP(5)GΔ60b, and containing an epitope tag within the duplication, rHRSVB05EGFP(5)Gmycb, were generated. A serial passage experiment was set up using rHRSVB05EGFP(5) and rHRSVB05EGFP(5)GΔ60b to understand the mutations that accumulate in the G protein gene of each virus. This will be valuable in setting up a similar experiment in the presence of immune pressure to understand the advantage that is conferred to the virus containing the duplication. Expression of Gmyc was confirmed in rHRSVB05EGFP(5)Gmyc infection, which validated that this virus can be used to study the HRSVB05 G protein and modifications in the duplicated region. The HRSV large (L) protein is essential in HRSV transcription and replication, but is difficult to study due to lack of immunologic reagents and challenges with purification. Recombinant viruses expressing reporter and polymerase fusion proteins have been generated and used for studying various other viral polymerases. Expression plasmids for HRSV L protein containing a reporter protein in its variable region 2 have been published. However, the modification resulted in downregulation in the function of the protein and rHRSV expressing modified L protein have not yet been published. In this study, rHRSVB05LVenus was generated to study the effects of modification of HRSV L protein variable region and the localization of HRSV L protein. LVenus protein in rHRSVB05LVenus infected cells was visualized by confocal laser scanning microscopy and the expression levels were examined by immunoblotting. rHRSVB05LVenus was compared to rHRSVB05EGFP(5) with unmodified L protein to show that modification of HRSV L protein had no effect on virus replication. Viruses had equivalent growth kinetics and were equally sensitive to ribavirin, a known HRSV inhibitor. The recombinant viruses generated in this study are valuable tools in answering questions that are difficult to pursue without clinically relevant recombinant viruses. Characterization of the rHRSVs demonstrated that these viruses will have many applications. In this study, viruses were characterized for the basic growth kinetics, expression of proteins of interest, and assay development. With these validated tools, questions such as the cause of the epidemiological pattern observed for HRSV A and B subtypes, the role of host immune response in advantage conferred to HRSV BA genotype, and the effects of inhibitors to formation of HRSV polymerase complex can be addressed. / 2018-10-31T00:00:00Z

Para fármacos administrados por via oral, o controle da extensão e da velocidade de absorção depende basicamente de duas importantes etapas: solubilidade do fármaco nos líquidos fisiológicos e sua permeabilidade através das membranas biológicas. Assim, o Sistema de Classificação Biofarmacêutica (SCB) foi proposto como uma ferramenta para o desenvolvimento de novos fármacos, de novas formulações e para auxiliar nos processos de bioisenção. No entanto, outro fator relacionado à biodisponibilidade e que deve ser considerado nos estudos biofarmacêuticos é o metabolismo. Desta forma, o Sistema de Classificação Biofarmacêutica de Distribuição de Fármacos (SCBDF) foi proposto com a finalidade de classificar os fármacos de acordo com suas características de solubilidade e de metabolismo de modo que seja possível avaliar e predizer o comportamento do fármaco in vivo. O metabolismo tem sido amplamente investigado, sobretudo as enzimas do citocromo P450, as quais estão presentes também nos enterócitos. Além disso, o SCBDF oferece um suporte quanto à avaliação dos mecanismos de permeabilidade envolvidos nos processos de absorção, interações fármaco-fármaco e interações fármaco-alimento. Assim, o presente trabalho teve como objetivo elucidar os mecanismos envolvidos na permeabilidade de fármacos antirretrovirais por meio dos modelos ex vivo (câmaras de difusão vertical tipo Franz) e in vitro (PAMPA, MDCK-MDR1 e microssomas) considerando os aspectos relacionados ao metabolismo intestinal e ao efluxo destes fármacos. Dada a importância da utilização de fármacos antirretrovirais na terapia medicamentosa contra a Síndrome da Imunodeficiência Adquirida (SIDA) e que estes medicamentos são normalmente administrados cronicamente, a compreensão dos mecanismos envolvidos na permeabilidade é de suma importância, uma vez que estes não estão totalmente esclarecidos e poucas informações são encontradas na literatura. Além disso, a biodisponibilidade de fármacos como estavudina, lamivudina e zidovudina indica variação na permeabilidade, necessitando de uma investigação científica mais aprofundada dos processos absortivos. Assim, segmentos de jejuno provenientes de ratos machos Wistar foram utilizados para a avaliação da permeabilidade intestinal dos referidos antirretrovirais considerando a avaliação de efluxo pela glicoproteína-P e o metabolismo intestinal pela CYP3A. De maneira complementar, estudos in vitro com o emprego de membranas artificiais paralelas (PAMPA) e culturas celulares de MDCK-MDR1 foram realizados com a finalidade de auxiliar na elucidação dos mecanismos de permeabilidade dos fármacos antirretrovirais. Além disso, a avaliação do metabolismo dos referidos fármacos foi realizada com o emprego de microssomas a fim de verificar se tais substâncias são substratos de enzimas da família CYP3A e, assim, verificar o impacto do metabolismo intestinal na absorção. Os resultados de permeabilidade obtidos em PAMPA foram: 0,74±0,11 x 10-6 cm/s para a estavudina, 0,25±0,12 x 10-6 cm/s para a lamivudina e 1,14±0,25 x 10-6 cm/s para a zidovudina. Já no modelo ex vivo com o emprego de câmaras de difusão vertical tipo Franz, os resultados foram: 1,56±0,32 x 10-5 cm/s para a estavudina, 1,26±0,27 x 10-5 cm/s para a lamivudina e 2,54±0,49 x 10-5 cm/s para a zidovudina. Portanto, com base nos resultados obtidos a partir dos dois métodos empregados, sugere-se que 30 outro mecanismo de transporte que não envolva a permeabilidade por difusão transcelular passiva possa estar relacionado à permeabilidade dos fármacos antirretrovirais. Com relação aos estudos de efluxo, os resultados obtidos a partir dos experimentos realizados em câmaras de difusão vertical tipo Franz demonstraram o aumento significativo da permeabilidade dos três antirretrovirais quando o inibidor de P-gp foi empregado, sendo: de 15,6 x 10-6 para 42,5 x 10-6 cm/s para a estavudina, de 12,6 x 10-6 para 37,5 x 10-6 cm/s para a lamivudina e de 25,4 x 10-6 para 56,6 x 10-6 cm/s para a zidovudina. Em culturas celulares MDCK-MDR1, os resultados de permeabilidade foram utilizados para a obtenção das razões entre as direções B→A e A→B. Os valores de Papp na condição inibida para os fármacos estudados apresentaram razão menor do que 1. Já a razão B→A/A→B para cada fármaco nos ensaios sem inibidor apresentou-se igual ou maior que 2, evidenciando a interação fármaco-transportador. Com base nisso, o modelo ex vivo com o emprego de segmentos intestinais em câmaras de difusão vertical tipo Franz apresentou-se adequado na avaliação do mecanismo de efluxo dos fármacos antirretrovirais, o que foi confirmado com os estudos realizados em MDCK-MDR1. Assim, os fármacos antirretrovirais estudados apresentaram interação significativa com a P-gp. Em relação aos estudos de metabolismo realizados em câmaras de difusão vertical tipo Franz, os resultados demonstraram grande variação na permeabilidade dos três antirretrovirais quando o inibidor de CYP3A foi empregado, sendo: de 15,6 x 10-6 para 23,5 x 10-6 cm/s para a estavudina, de 12,6 x 10-6 para 27,3 x 10-6 cm/s para a lamivudina e de 25,4 x 10-6 para 40,5 x 10-6 cm/s para a zidovudina. Já no modelo que emprega microssomas, os resultados de metabolização na ausência e na presença de inibidor de CYP3A foram: de 16,56% para 19,79% para a estavudina, de 14,56% para 15,55% para a lamivudina e de 17,85% para 16,48% para a zidovudina. Com base nisso, sugerese o emprego de microssomas para a determinação de metabolismo, uma vez que o método ex vivo empregado demonstrou grande variação entre os valores obtidos. Desta forma, observou-se que, para cada fármaco, não houve influência significativa no metabolismo pré-sistêmico relacionado às enzimas do complexo CYP3A, o que indica que a absorção oral das referidas substâncias não é limitada por tais enzimas. Portanto, a utilização dos diferentes métodos empregados no desenvolvimento do presente trabalho permitiu compreender os mecanismos envolvidos no transporte dos fármacos antirretrovirais, o que se torna de grande relevância nas etapas de desenvolvimento farmacêutico de novas moléculas e na compreensão de eventos clínicos ainda não esclarecidos atualmente. / For orally administered drugs, control of the extent and rate of absorption depends on two important steps: solubility of the drug in physiological liquids and their permeability across biological membranes. Thus, the Biopharmaceutics Classification System (BCS) has been proposed as a tool for the development of new drugs, new formulations and aid in the biowaiver processes. However, another factor related to bioavailability that should be considered in biopharmaceutic studies is the metabolism. Thus, the Biopharmaceutics Drug Disposition Classification System (BDDCS) has been proposed for drug classification according to their solubility and metabolism characteristics, so it is possible to evaluate and predict the in vivo behavior of a compound. Metabolism has been extensively investigated, especially cytochrome P450 enzymes, which are also expressed in enterocytes. Besides, BDDCS provides support in evaluating the permeability mechanisms involved in the absorption processes, drug-drug interactions and drug-food interactions. Thus, the present study aimed to evaluate the mechanisms of permeability of antiretroviral drugs through the ex vivo (Franz cells) and in vitro (PAMPA, MDCK-MDR1 and microsomes) models considering aspects related to the intestinal metabolism and efflux of these drugs. Given the importance of the use of antiretroviral drugs in drug therapy against Acquired Immune Deficiency Syndrome (AIDS) and that these drugs are usually administered in a long-term way, understanding the mechanisms involved in the permeability is of a great importance, since they are not totally elucidated and no information is found in the literature. In addition, drugs as stavudine, lamivudine and zidovudine indicate variation in the permeability, which require further scientific investigation of absorptive processes. Thus, jejunum segments from rats were used to evaluate the intestinal permeability of these antiretroviral drugs, considering the evaluation of efflux by P-glycoprotein and intestinal metabolism by CYP3A. In a complementary manner, in vitro studies using parallel artificial membranes (PAMPA) and cell cultures MDCK-MDR1 were performed to aid in the elucidation of the permeability mechanisms of antiretroviral drugs. Also, the evaluation of the metabolism was carried out using microsomes to verify if such substances are substrates of CYP3A, and verify the impact of the intestinal metabolism in the absorption. The permeability results obtained in PAMPA were: 0.74±0.11x10-6 cm/s for stavudine, 0.25±0.12x10-6 cm/s for lamivudine and 1.14±0.25x10-6 cm/s for zidovudine. In ex vivo method using the intestinal segments in Franz cells, the results were: 1.56±0.32x10-5 cm/s for stavudine, 1.26±0.27x10-5 cm/s for lamivudine and 2.54±0.49x10-5 cm/s for zidovudine. Thus, based on the results obtained from these two methods, it is suggested that the antiretroviral drugs present other transport mechanism that is different from transcellular passive diffusion. For efflux studies, results obtained from experiments performed in Franz cells shown the increase of the permeability of the three antiretroviral drugs when the P-gp inhibitor was used: from 15.6x10-6 to 42,5x10-6 cm/s for stavudine, from 12.6x10-6 cm/s to 37.5x10-6 cm/s for lamivudine, and 25.4x10-6 to 56.6x10-6 cm/s for zidovudine. In MDCK-MDR1, the permeability results were used for obtaining ratio values between the directions B→A and A→B. The Papp values obtained with 33 inhibitor shown a ratio less than 1. For ratio B→A/A→B for each drug in experiments without inhibitor, the values obtained was equal or greater than 2, which shows the interaction between drug and transporter. Based on that, the ex vivo model using intestinal segments in Franz cells seems to be adequate for evaluation of efflux mechanism of antiretroviral drugs, which was confirmed by MDCK-MDR1 studies. Thus, the antiretroviral drugs presented interaction with P-gp. For metabolism studies in intestinal segments in Franz cells, a wide range of standard deviation was observed for the three antiretroviral drugs when the CYP3A inhibitor was used: from 15.6x10-6 cm/s to 23.5x10-6 cm/s for stavudine, from 12.6x10-6 cm/s to 27.3x10-6 cm/s for lamivudine, and from 25.4x10-6 cm/s to 40.5x10-6 cm/s for zidovudine. In experiments in microsomes, the results of metabolization in the absence and presence of CYP3A inhibitor were: from 16.56 to 19.79% for stavudine, from 14.56 to 15.55% for lamivudine and from 17.85 to 16.48% for zidovudine. Based on that, it is suggested the use of microsomes for metabolism evaluation, since the ex vivo method presented high variability between the results obtained. For each drug, no significative influence in pre-systemic metabolism related to CYP3A enzymes was observed, which indicates that the oral absorption of the drugs is not limited by these enzymes. The use of different methods in this work allowed to understand the mechanisms involved in the transport of antiretroviral drugs, which is of a great relevance in drug development and in the understanding of clinical events currently not clarified.

Human immunodeficiency virus type 1 (HIV-1) establishes a persistent infection that leads to acquired immunodeficiency syndrome (AIDS). Approximately 36 million people worldwide are living with HIV-1, which is commonly acquired through sexual contact. Antiviral therapies control disease progression, but do not eliminate this virus from the host. Thus, global efforts are focused on developing vaccines that prevent HIV-1 transmission. Such vaccines are based on eliciting the production of protective antibodies that target the envelope glycoproteins (Envs) of this virus. Unfortunately, HIV-1 immunization trials have shown limited efficacy. A better understanding of the antibody-mediated inactivation process is needed to improve vaccine strategies. In this work we describe two novel factors that contribute to HIV-1 inactivation. First, we show that structural stability of the Env protein determines its sensitivity to vaccine-elicited antibodies. Different interactions within Env contribute to its stability. Perturbation of the Env-stabilizing interactions by physical and chemical treatments enhances sensitivity of HIV-1 to antibodies. Second, we found that the chemical composition of the transmission medium affects Env inhibition by antibodies and other inhibitory agents. Semen is the most common vehicle for HIV-1 transmission. This medium contains high concentrations of the sugar fructose. We found that semen fructose competitively blocks binding of antiviral agents that target sugar residues on Env. Together, this work advances our understanding of the mechanism that underlies HIV-1 inactivation by vaccine-elicited antibodies and provides novel strategies to enhance their potency.